Tricida Inc (NASDAQ:TCDA) Director Sandra I. Coufal sold 2,000 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $35.92, for a total value of $71,840.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
TCDA stock opened at $33.23 on Friday. The company has a current ratio of 8.30, a quick ratio of 8.30 and a debt-to-equity ratio of 0.24. Tricida Inc has a 12-month low of $19.43 and a 12-month high of $42.80. The firm has a market cap of $1.66 billion and a PE ratio of -7.16. The business has a 50-day moving average price of $36.29.
Tricida (NASDAQ:TCDA) last issued its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.10). As a group, equities research analysts anticipate that Tricida Inc will post -3.44 earnings per share for the current fiscal year.
Several analysts have issued reports on the company. Goldman Sachs Group assumed coverage on Tricida in a research report on Wednesday, June 26th. They set a “buy” rating and a $48.00 target price on the stock. Needham & Company LLC raised their price objective on ViaSat from $78.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 24th. Zacks Investment Research cut Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Cowen reissued a “buy” rating and issued a $50.00 price objective on shares of Tricida in a research report on Tuesday, June 25th. Finally, Empire raised their price objective on Tricida from $37.00 to $58.00 in a research report on Monday, April 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $47.00.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Story: How is a price target determined?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.